Authors: Sadock, Benjamin James; Sadock, Virginia Alcott
Title: Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry, 10th Edition
Copyright 2007 Lippincott Williams & Wilkins
> Table of Contents > 12 - Substance-Related Disorders > 12.4 - Caffeine-Related Disorders
Caffeine is the most widely consumed psychoactive substance in the world. Although numerous studies have documented the safety of caffeine when used in typical daily doses, psychiatric symptoms and disorders can be associated with its use. Although rates for these disorders are not well established, even a low prevalence could still result in a considerable number of people with these disorders because of the widespread use of caffeine.
The text revision of the 4th edition of the American Psychiatric Association's Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) recognizes several caffeine-related disorders (e.g., caffeine intoxication, caffeine-induced anxiety disorder, and caffeine-induced sleep disorder). Other caffeine-related disorders, such as caffeine withdrawal and caffeine dependence, are not official diagnoses in DSM-IV-TR, but they can also be of clinical interest.
Caffeine is contained in drinks, foods, prescription medicines, and over-the-counter medicines (Table 12.4-1). An adult in the United States consumes about 200 mg of caffeine per day on average, although 20 to 30 percent of all adults consume more than 500 mg per day. The per capita use of coffee in the United States is 10.2 pounds per year. A cup of coffee generally contains 100 to 150 mg of caffeine; tea contains about one third as much. Many over-the-counter medications contain one third to one half as much caffeine as a cup of coffee, and some migraine medications and over-the-counter stimulants contain more caffeine than a cup of coffee. Cocoa, chocolate, and soft drinks contain significant amounts of caffeine, enough to cause some symptoms of caffeine intoxication in small children when they ingest a candy bar and a 12-ounce cola drink.
Table 12.4-1 Common Sources of Caffeine and Representative Decaffeinated Products
Caffeine consumption also varies by age. The average daily caffeine consumption of caffeine consumers of all ages is 2.79 mg/kg of body weight in the United States. A substantial amount of caffeine is consumed even by young children (i.e., more than 1 mg/kg for children between the ages of 1 and 5 years). Worldwide, estimates place the average daily per capita caffeine consumption at about 70 mg. According to DSM-IV-TR, the actual prevalence of caffeine-related disorders is unknown, but up to 85 percent of adults consume caffeine in any given year.
Persons with caffeine-related disorders are more likely to have additional substance-related disorders than are those without diagnoses of caffeine-related disorders. About two thirds of those who consume large amounts of caffeine daily also use sedative and hypnotic drugs.
After exposure to caffeine, continued caffeine consumption can be influenced by several different factors, such as the pharmacological effects of caffeine, caffeine's reinforcing effects, genetic predispositions to caffeine use, and personal attributes of the consumer.
Caffeine, a methylxanthine, is more potent than another commonly used methylxanthine, theophylline (Primatene). The half-life of caffeine in the human body is 3 to 10 hours, and the time of peak concentration is 30 to 60 minutes. Caffeine readily crosses the blood brain barrier. Caffeine acts primarily as an antagonist of the adenosine receptors. Adenosine receptors activate an inhibitory G protein (Gi) and, thus, inhibit the formation of the second-messenger cyclic adenosine monophosphate (cAMP). Caffeine intake, therefore, results in an increase in intraneuronal cAMP concentrations in neurons with adenosine receptors. Three cups of coffee are estimated to deliver so much caffeine to the brain that about 50 percent of the adenosine receptors are occupied by caffeine. Several experiments indicate that caffeine, especially at high doses or concentrations, can affect dopamine and noradrenergic neurons. Specifically, dopamine activity may be enhanced by caffeine, a hypothesis that could explain clinical reports associating caffeine intake with an exacerbation of psychotic symptoms in patients with schizophrenia. Activation of noradrenergic neurons has been hypothesized to be involved in the mediation of some symptoms of caffeine withdrawal.
Subjective Effects and Reinforcement
Single low to moderate doses of caffeine (i.e., 20 to 200 mg) can produce a profile of subjective effects in humans that is generally identified as pleasurable. Thus, studies have shown that such doses of caffeine result in increased ratings on measures such as well-being, energy and concentration, and motivation to work. In addition, these doses of caffeine produce decreases in ratings of feeling sleepy or tired. Doses of caffeine in the range of 300 to 800 mg (the equivalent of several cups of brewed coffee ingested at once) produce effects that are often rated as being unpleasant, such as anxiety and nervousness. Although animal studies have generally found it difficult to demonstrate that caffeine functions as a reinforcer, well-controlled studies in humans have shown that people choose caffeine over placebo when given the choice under controlled experimental conditions. In habitual users, the reinforcing effects of caffeine are potentiated by the ability to suppress low-grade withdrawal symptoms after overnight abstinence. Thus, the profile of caffeine's subjective effects and its ability to function as a reinforcer contribute to the regular use of caffeine.
Genetics and Caffeine Use
Some genetic predisposition may exist to continued coffee use after exposure to coffee. Investigations comparing coffee or caffeine use in monozygotic and dizygotic twins have shown higher concordance rates for monozygotic twins for total caffeine consumption, heavy use, caffeine tolerance, caffeine withdrawal, and caffeine intoxication, with heritabilities ranging between 35 and 77 percent. Multivariate structural equation modeling of caffeine use, cigarette smoking, and alcohol use suggests that a common genetic factor polysubstance use underlines use of these three substances.
Age, Sex, and Race
The relationship between long-term chronic caffeine use and demographical features, such as age, sex, and race, has not been widely studied. Some evidence suggests middle-aged people may use more caffeine, although caffeine use in adolescents is not uncommon. No known evidence indicates that caffeine use differs between men and women, and no data specifically address caffeine use for different races. Some evidence suggests that, for both children and adults in the United States, whites consume more caffeine than blacks.
Cigarette smokers consume more caffeine than nonsmokers. This observation may reflect a common genetic vulnerability to caffeine use and cigarette smoking. It may also be related to increased rates of caffeine elimination in cigarette smokers. Preclinical and clinical studies indicate that regular caffeine use can potentiate the reinforcing effects of nicotine.
Heavy use and clinical dependence on alcohol is associated with heavy use and clinical dependence on caffeine as well. Individuals with anxiety disorders tend to report lower levels of caffeine use, although one study showed that a greater proportion of heavy caffeine consumers also use benzodiazepines. Several studies have also shown high daily amounts of caffeine use in psychiatric patients. For example, several studies have found that such patients consume the equivalent of an average of five or more cups of brewed coffee each day. Finally, high daily caffeine consumption has also been noted in prisoners.
Although attempts have been made to link preferential use of caffeine to particular personality types, results from these studies do not suggest that any particular personality type is especially linked to caffeine use.
Effects on Cerebral Blood Flow
Most studies have found that caffeine results in global cerebral vasoconstriction, with a resultant decrease in cerebral blood flow (CBF), although this effect may not occur in persons over 65 years of age. According to one recent study, tolerance does not develop to these vasoconstrictive effects, and the CBF shows a rebound increase after withdrawal from caffeine. Some clinicians believe that caffeine use can cause a similar constriction in the coronary arteries and produce angina in the absence of atherosclerosis.
The diagnosis of caffeine intoxication or other caffeine-related disorders depends primarily on a comprehensive history of a patient's intake of caffeine-containing products. The history should cover whether a patient has experienced any symptoms of caffeine withdrawal during periods when caffeine consumption was either stopped or severely reduced. The differential diagnosis for caffeine-related disorders should include the following psychiatric diagnoses: generalized anxiety disorder, panic disorder with or without agoraphobia, bipolar II disorder, attention-deficit/hyperactivity disorder, and sleep disorders. The differential diagnosis should include the abuse of caffeine-containing over-the-counter medications, anabolic steroids, and other stimulants, such as amphetamines and cocaine. A urine sample may be needed to screen for these substances. The differential diagnosis should also include hyperthyroidism and pheochromocytoma.
The DSM-IV-TR lists the caffeine-related disorders (Table 12.4-2) and provides diagnostic criteria for caffeine intoxication (Table 12.4-3), but does not formally recognize a diagnosis of caffeine withdrawal, which is classified as a caffeine-related disorder not otherwise specified (Table 12.4-4). The diagnostic criteria for other caffeine-related disorders are contained in the sections specific for the principal symptom (e.g., as a substance-induced anxiety disorder for caffeine-induced anxiety disorder).
The DSM-IV-TR specifies the diagnostic criteria for caffeine intoxication (Table 12.4-3), including the recent consumption of caffeine, usually in excess of 250 mg. The annual incidence of caffeine intoxication is an estimated 10 percent, although some clinicians and investigators suspect that the actual incidence is much higher. The common symptoms associated with caffeine intoxication include anxiety, psychomotor agitation, restlessness, irritability, and psychophysiological complaints such as muscle twitching, flushed face, nausea, diuresis, gastrointestinal distress, excessive perspiration, tingling in the fingers and toes,
Table 12.4-2 DSM-IV-TR Caffeine-Related Disorders
Table 12.4-3 DSM-IV-TR Diagnostic Criteria for Caffeine Intoxication
Despite that the DSM-IV-TR does not include a diagnosis of caffeine withdrawal, several well-controlled studies indicate that caffeine withdrawal is a real phenomenon, and DSM-IV-TR gives research criteria for caffeine withdrawal (Table 12.4-5). The appearance of withdrawal symptoms reflects the tolerance and physiological dependence that develop with continued caffeine use. Several epidemiological studies have reported symptoms of caffeine withdrawal in 50 to 75 percent of all caffeine users studied. The most common symptoms are headache and fatigue; other symptoms include anxiety, irritability, mild depressive symptoms, impaired psychomotor performance, nausea, vomiting, craving for caffeine, and muscle pain and stiffness. The number and severity of the withdrawal symptoms are correlated with the amount of caffeine ingested and the abruptness of the withdrawal. Caffeine withdrawal symptoms have their onset 12 to 24 hours after the last dose; the symptoms peak in 24 to 48 hours and resolve within 1 week.
Table 12.4-4 DSM-IV-TR Diagnostic Criteria for Caffeine- Related Disorder Not Otherwise Specified
Table 12.4-5 DSM-IV-TR Research Criteria for Caffeine Withdrawal
The induction of caffeine withdrawal can sometimes be iatrogenic. Physicians often ask their patients to discontinue caffeine intake before certain medical procedures, such as endoscopy, colonoscopy, and cardiac catheterization. Physicians also often recommend that patients with anxiety symptoms, cardiac arrhythmias, esophagitis, hiatal hernias, fibrocystic disease of the breast, and insomnia stop caffeine intake. Some persons simply decide that it would be good for them to stop using caffeine-containing products. In all these situations, caffeine users should taper the use of caffeine-containing products over a 7- to 14-day period rather than stop abruptly.
Caffeine-Induced Anxiety Disorder
Caffeine-induced anxiety disorder, which can occur during caffeine intoxication, is a DSM-IV-TR diagnosis (see Table 16.7-3). The anxiety related to caffeine use can resemble that of generalized anxiety disorder. Patients with the disorder may be perceived as wired, overly talkative, and irritable; they may complain of not sleeping well and of having energy to burn. Caffeine can induce and exacerbate panic attacks in persons with a panic disorder and although a causative association between caffeine and a panic disorder has not yet been demonstrated, patients with panic disorder should avoid caffeine.
Caffeine-Induced Sleep Disorder
Caffeine-induced sleep disorder, which can occur during caffeine intoxication, is a DSM-IV-TR diagnosis (see Table 24.2-21). Caffeine is associated with delay in falling asleep, inability to remain asleep, and early morning awakening.
Caffeine dependence is not included in DSM-IV-TR, which explicitly states, A diagnosis of Substance Dependence can be
Ms. G was a 35-year-old married, white homemaker with three children, aged 8, 6, and 2. She took no prescription medications, took a multivitamin and vitamins C and E on a daily basis, did not smoke, and had no history of psychiatric problems. She drank moderate amounts of alcohol on the weekends, had smoked marijuana in college but had not used it since, and had no other history of illicit drug use.
She had started consuming caffeinated beverages while in college, and her current beverage of choice was caffeinated diet cola. Ms. G had her first soft drink early in the morning, shortly after getting out of bed, and she jokingly called it her morning hit. She spaced out her bottles of soft drinks over the course of the day, with her last bottle at dinnertime. She typically drank four to five 20-oz bottles of caffeinated diet cola each day.
She and her husband had argued about her caffeinated soft drink use in the past, and her husband had believed she should not drink caffeinated soft drinks while pregnant. However, she had continued to do so during each of her pregnancies. Despite a desire to stop drinking caffeinated soft drinks, she was unable to do so. She described having a strong desire to drink caffeinated soft drinks, and if she resisted this desire, she found that she could not think of anything else. She drank caffeinated soft drinks in her car, which had a manual transmission, and noted that she fumbled while shifting and holding the soft drink and spilled it in the car. She also noted that her teeth had become yellowed, and she suspected this was related to her tendency to swish soft drink in her mouth before swallowing it. When asked to describe a time when she stopped using soft drinks, she reported that she had run out of it on the day one of her children was to have a birthday party, and she did not have time to leave her home to buy more. In the early afternoon of that day, a few hours before the scheduled start of the party, she felt extreme lethargy, a severe headache, irritability, and craving for a soft drink. She called her husband and told him she planned to cancel the party. She then went to the grocery store to buy soft drinks, and after drinking two bottles, she felt well enough to host the party.
Although initially expressing interest in decreasing or stopping her caffeinated soft drink use, Ms. G did not attend scheduled follow-up appointments after her first evaluation. When finally contacted at home, she reported she had only sought help initially at her husband's request, and she had decided to try to cut down on her caffeine use on her own. (Courtesy of Eric Stain, M.D.)
Caffeine-Related Disorder Not Otherwise Specified
The DSM-IV-TR contains a residual category for caffeine-related disorders that do not meet the criteria for caffeine intoxication, caffeine-induced anxiety disorder, or caffeine-induced sleep disorder (Table 12.4-4).
Signs and Symptoms
After the ingestion of 50 to 100 mg of caffeine, common symptoms include increased alertness, a mild sense of well-being, and a sense of improved verbal and motor performance. Caffeine ingestion is also associated with diuresis, cardiac muscle stimulation, increased intestinal peristalsis, increased gastric acid secretion, and (usually mildly) increased blood pressure.
Caffeine Use and Nonpsychiatric Illnesses
Despite numerous studies examining the relationship between caffeine use and physical illness, significant health risk from nonreversible pathological consequences of caffeine use, such as cancer, heart disease, and human reproduction, has not been conclusively demonstrated. Nonetheless, caffeine use is often considered to be contraindicated for various conditions, including generalized anxiety disorder, panic disorder, primary insomnia, gastroesophageal reflux, and pregnancy. In addition, the modest ability of caffeine to increase blood pressure and the documented cholesterol-elevating compounds of unfiltered coffee have raised the issue of the relationship of caffeine and coffee use to cardiovascular disease. Finally, there may be a mild association between higher daily caffeine use in women and delayed conception and slightly lower birth weight. Studies, however, have not found such associations, and effects, when found, are usually with relatively high daily dosages of caffeine (e.g., the equivalent of five cups of brewed coffee per day). For a woman who is considering pregnancy, especially if there is some difficulty in conceiving, it may be useful to counsel eliminating caffeine use. Similarly, for a woman who becomes pregnant and has moderate to high daily caffeine consumption, a discussion about decreasing her daily caffeine use may be warranted.
Analgesics, such as aspirin, almost always can control the headaches and muscle aches that may accompany caffeine withdrawal. Rarely do patients require benzodiazepines to relieve withdrawal symptoms. If benzodiazepines are used for this purpose, they should be used in small dosages for a brief time, about 7 to 10 days at the longest.
The first step in reducing or eliminating caffeine use is to have patients determine their daily consumption of caffeine. This can best be accomplished by having the patient keep a daily food diary. The patient must recognize all sources of caffeine in the diet, including forms of caffeine (e.g., beverages, medications), and accurately record the amount consumed. After several days of keeping such a diary, the clinician can meet with the patient, review the diary, and determine the average daily caffeine dose in milligrams.
The patient and clinician should then decide on a fading schedule for caffeine consumption. Such a schedule could involve a decrease in increments of 10 percent every few days. Because caffeine is typically consumed in beverage form, the patient can use a substitution procedure in which a decaffeinated beverage is gradually used in place of the caffeinated beverage. The diary should be maintained during this time, so that the patient's progress can be monitored. The fading should be
Casas M, Ramos-Quiroga JA, Prat G, Qureshi A. Effects of coffee and caffeine on mood and mood disorders. In: Nehlig A, ed. Coffee, Tea, Chocolate, and the Brain. Boca Raton: CRC Press; 2004:73 83.
Cauli O, Pinna A, Valentini V, Morelli M. Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology. 2003;28:1752 1759.
Griffiths RR, Juliano LM, Chausmer AL. Caffeine pharmacology and clinical effects. In: Graham AW, Schultz TK, Mayo-Smith M, Ries RK, Wilford BB, eds. Principles of Addiction Medicine. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003.
Kushner M. The Truth About Caffeine: How Companies That Promote It Deceive Us and What We Can Do About It. New York: SCR Books, LLC; 2006.
McCusker RR, Goldberger BA, Cone EJ. Caffeine content of specialty coffees. J Anal Toxicol. 2003;27:520 522.
Nawrot P, Jordan S, Eastwood J, Rotstein J, Hugenholtz A, Feeley M. Effects of caffeine on human health. Food Addit Contam. 2003;20:1 30.
Orbeta RL, Overpeck MD, Ramcharran D, Kogan MD, Ledsky R. High caffeine intake in adolescents: Associations with difficulty sleeping and feeling tired in the morning. J Adolesc Health. 2006;38(4):451 453.
Rogers PJ, Martin J, Smith C, Heatherley SV, Smit HJ. Absence of reinforcing, mood and psychomotor performance effects of caffeine in habitual non-consumers of caffeine. Psychopharmacology (Berl). 2003;167:54 62.
Strain EC, Griffiths RR. In: Sadock BJ, Sadock VA, eds. Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 8th ed. Vol. 1. Baltimore: Lippincott Williams & Wilkins; 2005:1201.
Striegel-Moore RH, Franko DL, Thompson D, Barton B, Schreiber GB, Daniels SR. Caffeine intake in eating disorders. Int J Eat Disord. 2006;39:162 165.
Tinley Em, Yeomans MR, Durlach PJ. Caffeine reinforces flavour preference in caffeine-dependent, but not long-term withdrawn, caffeine consumers. Psychopharmacology (Berl). 2003;166:416 423.